NCT06482853View on ClinicalTrials.gov

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 23, 2025

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions
ObesityHypertension
Interventions
DRUG

Angiotensin-(1-7)

This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.

DRUG

Saline

Saline will be used as the placebo comparator.

Trial Locations (1)

17033

RECRUITING

Penn State Milton S. Hershey Medical Center, Hershey

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Milton S. Hershey Medical Center

OTHER